Industrial biotech company presents update and additional growth plan at leading industry conference
Milton, Massachusetts, USA (Nov. 15, 2021) – Kalion, Inc., a growing industrial biotech company providing low-cost access to high-purity and environmentally friendly glucaric solutions, today announced it is one step closer to full commercialization of its glucaric acid product with recently completed custom manufacturing at Evonik in Europe.
Darcy Prather, Kalion founder and CEO, presented an update on the successful custom manufacturing campaign and the company’s growth and commercialization activities at the Alternative Fuels & Chemicals Coalition conference in Washington, DC, on Nov. 15, 2021. He also provided an overview of how biotechnology offers access to a new world of chemicals with unique advantages over drop-in products not easily accessed from petroleum.
Kalion uses synthetic biology to produce highly effective, low-cost and environmentally friendly glucaric acid and its derivatives. The completion of the custom manufacturing campaign will allow the company to meet existing, multiple customer commitments and demand through summer 2022 and have limited quantities available for additional customers interested in evaluating high-purity glucaric products.
“Kalion can now produce commercial quantities of glucaric acid with the quality and cost necessary to allow companies across a wide range of industry to introduce higher performing, renewable solutions to critical issues across their business,” Prather said. “Having worked closely with two leading water treatment companies to demonstrate the effectiveness of our first solution, KSPG40, the Kalion team will now deliver the product at scale to the water treatment sector that has been seeking a cost-effective replacement for phosphates.”
Glucaric acid and its related compounds enhance sustainability as well as improve the performance of products and applications ranging from water treatment, polymers and textiles, coatings, detergents, and pharmaceuticals.
To address specific customer needs, Evonik has established a broad portfolio of advanced technologies which can be combined to support multi-step API synthesis. These technologies include continuous processing, fermentation, highly pure PEGs and
mPEGs, transition metal catalysis, biocatalysis, organometallic/cryogenic chemistry, and Chemistry in Water. For many specialized therapy areas, Evonik serves as a fully integrated CMO with capabilities to manufacture customized APIs, select and supply functional excipients, develop parenteral or oral formulations, and manufacture finished drug products. In addition to this integrated portfolio of services, many customers are also attracted by Evonik’s reliability and commitment to sustainability.
Kalion’s KSPG40 glucaric acid is a powerful corrosion inhibitor that presents several advantages over phosphates in water treatment:
Kalion, Inc. is a Massachusetts-based bioengineering company bringing innovative cost-effective, bio-based solutions to challenging environmental problems. Providing low-cost, high-purity glucaric acid, Kalion has introduced solutions for challenges in industries ranging from water treatment to textiles that improve both the economics and environmental profile of a variety of products. Kalion received the U.S. EPA’s Green Chemistry Challenge Award in 2019.
###